Creative Biolabs Launches Integrated Cell Therapy Platforms to Advance Cancer Immunotherapy
Creative Biolabs has launched fully integrated CAR-T and TIL therapy development platforms, providing researchers and biotech startups with comprehensive services to accelerate the development of next-generation cellular immunotherapies for cancer treatment.
Creative Biolabs announced the full integration of its one-stop-shop CAR-T and TIL therapy development platforms, offering researchers and biotech startups a seamless, end-to-end service for developing next-generation cellular immunotherapies. This development comes at a critical time when recent regulatory approvals, such as the FDA approval of lifileucel (Amtagvi)—the first tumor-infiltrating lymphocyte therapy for advanced melanoma—have demonstrated the significant therapeutic potential of cell-based cancer treatments.
The company's Smart™ CAR platform is designed to push boundaries through construction services for advanced CAR designs, including novel constructs such as Dual CARs, TriCARs, Modular CAR, and Logic-gated CAR. According to a principal scientist at Creative Biolabs, "Our goal is not just to build potent CARs—we're building smart CARs." The platform supports first- through fourth-generation CARs, along with armored variants that secrete immune modulators like IL-12, with each construct tailored to tumor biology and immune microenvironment for optimal efficacy and minimal toxicity.
The CAR-T platform targeting solid tumors addresses one of the most challenging obstacles in the field: penetrating the immunosuppressive defenses of solid tumors. Creative Biolabs employs bispecific CARs, checkpoint-resistant designs, and optimized delivery systems for improved infiltration and persistence. Meanwhile, the tumor-infiltrating lymphocyte therapy platform represents a breakthrough innovation in treating solid tumors, providing comprehensive and integrated services to meet the field's refined needs.
A company representative noted that "TIL therapy is exceptionally well-positioned to identify heterogeneous neoantigens," and Creative Biolabs also leads in TIL-based antibody discovery, utilizing patient-derived B cells to develop fully human antibodies with high specificity and therapeutic value. The company integrates cutting-edge technologies to facilitate accelerated and stable translation from bench to bedside, employing the latest in genetic and cellular engineering to ensure TILs are highly potent and specifically targeted against cancer cells. Researchers can learn more about these services by visiting https://www.creative-biolabs.com/car-t/.
With innovations in off-the-shelf CAR-NKT and armored CAR-T technologies pushing the boundaries of what can be achieved with engineered immune cells, Creative Biolabs positions itself at the forefront by offering platforms that combine scientific rigor, technological innovation, and clinical scalability. This integrated approach provides the research community with essential tools to advance cancer immunotherapy development and potentially bring more effective treatments to patients worldwide.